نتایج جستجو برای: pomalidomide

تعداد نتایج: 497  

Journal: :Blood 2015
Jatin J Shah Edward A Stadtmauer Rafat Abonour Adam D Cohen William I Bensinger Cristina Gasparetto Jonathan L Kaufman Suzanne Lentzsch Dan T Vogl Christina L Gomes Natalia Pascucci David D Smith Robert Z Orlowski Brian G M Durie

Treatment options for patients with heavily pretreated relapsed and/or refractory multiple myeloma remain limited. We evaluated a novel therapeutic regimen consisting of carfilzomib, pomalidomide, and dexamethasone (CPD) in an open-label, multicenter, phase 1, dose-escalation study. Patients who relapsed after prior therapy or were refractory to the most recently received therapy were eligible....

2017
Alessandra Larocca Roberto Mina Francesca Gay Sara Bringhen Mario Boccadoro

In the past few years, multiple targeted therapies and immunotherapies including second generation immunomodulatory drugs (pomalidomide) and proteasome inhibitors (carfilzomib, ixazomib), monoclonal antibodies and checkpoint inhibitors were approved for the treatment of myeloma or entered advanced phases of clinical testing. These agents showed significant activity in advanced myeloma and incre...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2016
Richard J Jones Tawin Iempridee Xiaobin Wang Hans C Lee Janet E Mertz Shannon C Kenney Heather C Lin Veerabhadran Baladandayuthapani Christopher W Dawson Jatin J Shah Donna M Weber Robert Z Orlowski

PURPOSE Lenalidomide, thalidomide, and pomalidomide (LTP) are immunomodulatory agents approved for use in multiple myeloma, but in some settings, especially with alkylating agents, an increase in Hodgkin lymphoma and other secondary primary malignancies (SPM) has been noted. Some of these malignancies have been linked to Epstein-Barr virus (EBV), raising the possibility that immunomodulatory dr...

Journal: :Leukemia & Lymphoma 2013

Journal: :Endocrinology, Diabetes & Metabolism Case Reports 2017

2016
Yasunobu Sekiguchi Tadaaki Inano Yasutaka Fukuda Haruko Takizawa Mutsumi Wakabayashi Keiji Sugimoto Shigeki Tomita Hiroshi Izumi Noriko Nakamura Tomohiro Sawada Yasunori Ohta Norio Komatsu Masaaki Noguchi

In June 2011, a 66-year-old woman was diagnosed as multiple myeloma (IgG-k type). In July 2011, she received bortezomib and dexamethasone therapy with a 5-week cycle. After the third treatment cycle, the patient showed disease progression to secondary plasma cell leukemia. In September 2011, lenalidomide and dexamethasone therapy was initiated with a 4-week cycle; however, the patient remained ...

2017
Elisabeth Bertrand Nathalie Jouy Salomon Manier Guillemette Fouquet Stéphanie Guidez Eileen Boyle Stéphanie Noel Cécile Tomowiak Charles Herbaux Susanna Schraen Claude Preudhomme Bruno Quesnel Stéphanie Poulain Xavier Leleu

Background Immunomodulatory drugs, IMid compounds, are active in Waldenström's macroglobulinemia (WM), although in a lesser extent than multiple myeloma, where it was initially developed. We hypothesized WM tumour cells might develop mechanisms of resistance, and sought to identify and describe these mechanisms. Material and Method MM and WM-derived cell lines, and Waldenström's CD19+ cells w...

Journal: :The Journal of Clinical Pharmacology 2015

Journal: :Expert Opinion on Pharmacotherapy 2016

2016
Rachid C Baz Thomas G Martin Hui-Yi Lin Xiuhua Zhao Kenneth H. Shain Hearn J. Cho Jeffrey L. Wolf Anuj Mahindra Ajai Chari Daniel M. Sullivan Lisa A. Nardelli Kenneth Lau Melissa Alsina Sundar Jagannath H. Lee Moffitt

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید